预约演示
更新于：2025-03-04
Meropenem
美洛培南
更新于：2025-03-04
概要
基本信息
药物类型 小分子化药 |
别名 Belopenem、Mepem、Meropen + [20] |
靶点 |
作用机制 PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂) |
在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C17H27N3O6S |
InChIKeyWCDAAZJSDNCCFU-NACOAMSHSA-N |
CAS号119478-56-7 |
关联
167
项与 美洛培南 相关的临床试验CTR20243916
注射用HRS-2183在中国健康受试者中单次给药的安全性、耐受性、药代动力学研究以及与美罗培南的药物相互作用研究
CTRI/2024/08/073105
A COMPARATIVE STUDY OF CEFOTAXIME VS MEROPENEM AS EMPIRICAL TREATMENT IN SPONTANEOUS BACTERIAL PERITONITIS - SBP CURE
IRCT20111107008022N16
Therapeutic drug monitoring of meropenem in patients hospitalized in intensive care units of hamadan hospitals
100 项与 美洛培南 相关的临床结果
登录后查看更多信息
100 项与 美洛培南 相关的转化医学
登录后查看更多信息
100 项与 美洛培南 相关的专利（医药）
登录后查看更多信息
31,799
项与 美洛培南 相关的文献（医药）2025-05-01Journal of Global Antimicrobial Resistance
First report of an Enterobacter cloacae ST837 resistant to cefiderocol co-harbouring blaIMP-19 and mcr-4.3 resistance genes in Italy
Article
作者: Secci, Benedetta ; Foschi, Claudio ; Menozzi, Ilaria ; Ambretti, Simone ; Scaltriti, Erika ; Lazzarotto, Tiziana ; Dodi, Alessandra ; Pongolini, Stefano
OBJECTIVES:
We described the molecular characterization of an Enterobacter cloacae strain resistant to cefiderocol, co-harbouring blaIMP-19 and mcr-4.3 resistance genes METHODS: The strain was isolated from the rectal swab of a 77-year-old woman during the screening for the detection of patients colonized by carbapenemase-producing Enterobacterales (CPE), in Bologna (Italy). The strain was identified at the species level by MALDI-TOF mass spectrometry and the presence of IMP carbapenemase was confirmed both by a phenotypic immunochromatographic method, and by a rapid commercial NAAT. The strain underwent an antimicrobial susceptibility testing and its genome was fully characterized to assess (i) the Multi Locus Sequence Type (MLST), (ii) the presence of antimicrobial resistance genes (AMR), (iii) the presence of virulence genes coupled with Mobile Genetic Elements.
RESULTS:
MLST identified the strain as ST837. A plasmid of 60'691 bp, very similar to MW574937 plasmid of Escherichia coli was identified and carried the following AMR genes: aac(6')-II,blaBEL-1, blaIMP-19, msr(E), mph(E), sul1. This plasmid harboured several tra gene (traB, traC, traD, traG, traI, traJ, traKtraL, traM) of the transfer operon of E. coli conjugative F plasmid. Other AMR genes were located in the chromosome (blaCMH-3 and fosA) or in other plasmids (blaSHV-12 and mcr-4.3). In vitro the strain showed resistance to many beta-lactams, including cefiderocol, whereas, despite the presence of mcr-4.3 gene, it was susceptible to colistin.
CONCLUSIONS:
Further studies are needed to better evaluate the origin of this strain, monitoring the presence of gram-negative bacilli with a similar molecular structure in our area.
2025-04-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
In vitro and in vivo efficacy studies of an engineered endolysin targeting Gram-negative pathogens
Article
作者: Kim, Min Soo ; Kim, Young Deuk ; Yoon, Hyunjin ; Myung, Heejoon ; Park, Kyungah ; Jang, Jaeyeon ; Lim, Daejin ; Hong, Hye-Won ; Lee, Dogeun ; Yoon, In-Soo ; Seo, Min-Duk ; Song, Miryoung ; Jeong, Tae-Hwan
Endolysins have drawn considerable attention as viable modalities for antibiotic use. The most significant obstacle for Gram-negative targeting endolysins is the presence of the outer membrane barrier. A heterologously expressed endolysin encoded by bacteriophage PBPA90 infecting Pseudomonas aeruginosa exhibited intrinsic antibacterial activity against P. aeruginosa. The antibacterial efficacy was improved by substituting 15 amino acids and by fusing cecropin A to the N-terminus. The resulting engineered endolysin, LNT103, demonstrated strong antibacterial activity, with minimum inhibitory concentrations as low as 4 μg/ml, against various Gram-negative pathogens in addition to P. aeruginosa, including Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae, Klebsiella aerogenes, and Enterobacter cloacae. The engineered endolysin rendered both the outer and the inner bacterial membranes permeable. It exhibited a synergistic effect with colistin, and additive effects with carbapenem antibiotics. Bacterial resistance development to LNT103 was none to minimal in vitro. Its in vivo efficacy was verified in bacteremia models of mice infected with A. baumannii. The endolysin led to a resensitization of resistant bacteria to meropenem when used in combination in vivo.
2025-04-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
PEN-FAST-ED: Utilizing the PEN-FAST decision tool to guide antibiotic prescribing in the emergency department
Article
作者: Kisgen, Jamie ; Langley, David ; Lund, Jeremy ; Tran, Kimberly ; Sealy, Chloe
BACKGROUND:
Patient-reported penicillin allergies are frequently encountered in the emergency department (ED), which often lead to non-beta-lactam antibiotic use despite beta-lactams' place as first-line therapy in most bacterial infections. The PEN-FAST clinical decision tool was developed and validated to identify patients with a low risk of true penicillin allergies that do not require formal skin testing for rechallenging. The tool consists of four questions that add up to a total score ranging from 0 to 5. Scores of 0-2 are associated with low risk of true penicillin allergy (<5% risk of true reaction); scores of 3 with moderate risk (<20% risk); and scores of 4-5 with high risk (50% risk). The purpose of our study was to determine the safety and efficacy of our facility's implementation of pharmacist utilization of the PEN-FAST screening tool to assess purported penicillin allergies and rechallenge low to moderate risk patients in the ED.
METHODS:
This was a single-center, prospective, observational cohort study conducted from October 2023 to March 2024. Adult ED patients with a documented penicillin allergy with an order for aztreonam, levofloxacin, clindamycin, or a consult for pharmacy to assist with antibiotic selection were included. Patients were excluded if the order or consult was placed by a non-ED physician, no penicillin allergy was documented, the patient had previously tolerated a penicillin or cephalosporin per chart review, was unable to participate in the interview, or the completion of the assessment would delay patient care. The primary outcome was the percent of patients with a PEN-FAST score of 0-2 who tolerated a beta-lactam antibiotic after pharmacist intervention. Secondary safety and logistical outcomes included the incidence of immune-mediated reactions within one hour of beta-lactam administration, timing of the assessment, and antibiotic selection in transitions of care.
RESULTS:
Of the 361 patients screened, 100 patients were included. There were 61% of patients who had a PEN-FAST score of 0-2, 30% had a score of 3, and 9% had a score of 4-5. For the primary outcome, all 52 (100%) patients with a PEN-FAST score of 0-2 who were rechallenged tolerated a beta-lactam antibiotic in the ED. For secondary outcomes, 6 patients with PEN-FAST score of 3 were rechallenged and tolerated a beta-lactam. There were 0 incidences of any immune-mediated reactions within one hour of beta-lactam administration. The median time from initial order placement to change in therapy and to antibiotic administration was 17 min and 41 min, respectively. Of those rechallenged, 13 of 14 discharged (93%) and 39 of 44 admitted patients (89%) were continued on beta-lactam antibiotics.
CONCLUSION:
In this prospective, observational study, administration of beta-lactam antibiotics to ED patients with previously reported penicillin allergies and a PEN-FAST score less than 3 did not result in any immune-mediated reactions. The PEN-FAST decision tool was able to safely identify and risk-stratify eligible patients for beta-lactam rechallenge in the ED.
100 项与 美洛培南 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 复杂腹腔感染 | 美国 | 2015-04-30 | |
| 社区获得性呼吸道感染 | 澳大利亚 | 1996-07-25 | |
| 复杂皮肤和皮肤结构感染 | 澳大利亚 | 1996-07-25 | |
| 复杂的尿路感染 | 澳大利亚 | 1996-07-25 | |
| 妇科感染 | 澳大利亚 | 1996-07-25 | |
| 医院获得性肺炎 | 澳大利亚 | 1996-07-25 | |
| 脑膜炎 | 澳大利亚 | 1996-07-25 | |
| 腹腔感染 | 美国 | 1996-06-21 | |
| 细菌性脑膜炎 | 美国 | 1996-06-21 | |
| 皮肤和皮肤结构感染 | 美国 | 1996-06-21 | |
| 细菌感染 | 日本 | 1995-09-04 | |
| 粒细胞减少性发热 | 日本 | 1995-09-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸机相关性肺炎 | 临床3期 | - | 2018-08-01 | |
| 脓肿 | 临床3期 | - | 2001-02-01 | |
| 蜂窝织炎 | 临床3期 | - | 2001-02-01 | |
| 肺炎 | 临床前 | 瑞典 | 2021-09-24 | |
| 感染 | 临床前 | 美国 | 2014-12-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 92 | Standard 24-h AP regimen | 鏇齋築鏇觸齋選夢襯廠(範餘壓網顧築齋夢壓膚) = 積簾鏇窪齋醖遞醖觸廠 鏇範遞艱蓋醖齋網鑰鹽 (繭範鹽壓襯製顧範願鬱 ) 更多 | 积极 | 2024-10-01 | |
Prolonged meropenem AP 120-h | 鏇齋築鏇觸齋選夢襯廠(範餘壓網顧築齋夢壓膚) = 衊獵醖鏇蓋憲積獵鬱範 鏇範遞艱蓋醖齋網鑰鹽 (繭範鹽壓襯製顧範願鬱 ) 更多 | ||||||
临床4期 | 35 | (Continuous Antibiotic Dose Over 24 Hours Arm) | 鹹膚憲簾製醖顧廠觸餘(壓觸繭鬱醖廠獵襯蓋製) = 鬱淵壓構餘築鬱鑰構積 繭獵製齋壓廠壓艱憲餘 (憲醖醖艱選遞繭蓋鏇鹹, 壓襯鹽廠鏇壓餘顧觸淵 ~ 鏇艱願鹹積獵築願繭襯) 更多 | - | 2023-12-12 | ||
(Intermittent Antibiotic Dose Over 30 Minutes) | 鹹膚憲簾製醖顧廠觸餘(壓觸繭鬱醖廠獵襯蓋製) = 簾鹽簾鏇艱淵鑰簾襯艱 繭獵製齋壓廠壓艱憲餘 (憲醖醖艱選遞繭蓋鏇鹹, 淵齋醖製憲鹹構鹽鹽鬱 ~ 願夢齋繭齋憲膚艱積鑰) 更多 | ||||||
FDA 人工标引  | N/A | 446 | 淵願鏇齋襯淵顧齋遞襯(鑰糧鬱齋構獵餘淵膚廠) = Most common adverse reactions (incidence ≥ 1%) are diarrhea, rash (mostly diaper area moniliasis), oral moniliasis, and glossitis. 憲網鬱醖醖積壓製築壓 (醖網壓積餘願淵蓋夢遞 ) | 积极 | 2023-07-26 | ||
临床2期 | 112 | (Rifampin Resistant A) | 築構遞餘願簾壓醖鏇鹹(襯獵襯願餘鹽艱膚壓壓) = 夢顧窪憲選膚願廠構範 構鏇繭窪製網構鹽廠醖 (膚鑰遞憲夢淵廠積鹹鹹, 築選觸鹽簾壓糧繭襯築 ~ 顧簾鏇淵淵艱衊構襯構) 更多 | - | 2023-07-19 | ||
(Rifampin Resistant B) | 築構遞餘願簾壓醖鏇鹹(襯獵襯願餘鹽艱膚壓壓) = 簾製網鹹鹹餘蓋鹹壓鹽 構鏇繭窪製網構鹽廠醖 (膚鑰遞憲夢淵廠積鹹鹹, 獵遞繭廠製遞廠夢願簾 ~ 遞憲膚襯糧願膚築壓艱) 更多 | ||||||
临床2期 | 二线 | 112 | 廠鬱餘築製齋淵鏇鹹願(繭廠鹽醖觸獵構艱糧構) = Tolerability of intravenous meropenem, with amoxicillin/clavulanate, though, was poor at all doses, calling into question the utility of this drug in second-line regimens. 夢襯壓淵壓遞網鑰襯鑰 (壓鹽獵糧觸遞膚廠衊壓 ) | 不佳 | 2022-03-08 | ||
Meropenem 2 grams 8 hourly plus rifampin 20 mg/kg once daily | |||||||
临床3期 | 467 | 廠網鬱壓夢夢窪鹹鬱製(積廠獵獵膚遞構壓積窪) = 簾壓餘積顧顧衊淵鬱糧 遞範夢膚獵積鑰憲繭鹹 (鑰網膚簾簾壓夢蓋夢鹹, 網繭襯鑰膚壓餘範繭製 ~ 襯夢願淵範遞網蓋膚選) 更多 | - | 2021-11-30 | |||
N/A | 426 | 鑰衊憲窪繭鏇憲襯廠製(製鹹鬱範簾築壓築鹽遞) = 艱鑰築淵壓襯製鏇鏇鏇 醖獵衊壓獵鹽願鹽築鏇 (觸遞壓積獵艱範鬱膚壓, 齋鬱糧餘齋餘窪願觸醖 ~ 夢齋壓築襯獵廠糧糧簾) 更多 | - | 2021-08-05 | |||
鑰衊憲窪繭鏇憲襯廠製(製鹹鬱範簾築壓築鹽遞) = 積齋選窪廠衊鏇範遞廠 醖獵衊壓獵鹽願鹽築鏇 (觸遞壓積獵艱範鬱膚壓, 鬱艱願憲構網憲壓憲憲 ~ 獵構鏇廠衊窪壓積願鏇) 更多 | |||||||
临床4期 | - | Piperacillin-tazobactam 4.5 g | 獵觸遞襯觸膚壓蓋蓋艱(糧網鑰繭廠築遞艱鏇鹹) = 憲觸夢願鏇餘淵襯衊範 鹽築顧鑰窪願蓋獵淵鏇 (繭選膚壓積網醖蓋壓鬱 ) | - | 2021-08-01 | ||
糧夢壓鏇鹹製憲簾醖襯(觸餘獵簾鹽簾艱構壓觸) = 築願範醖鏇蓋觸襯願範 網觸憲鬱襯積淵觸壓襯 (繭範繭積簾網鹹獵鏇積 ) | |||||||
N/A | 190 | Aerobic antibiotics | 醖淵膚襯願淵鬱襯鏇醖(選艱獵鹹鏇醖醖構製積) = 蓋廠衊憲壓遞顧繭淵憲 襯夢鏇夢簾獵廠淵襯壓 (鏇顧餘願範觸鹹範憲鏇 ) | - | 2021-06-09 | ||
N/A | - | 獵糧壓顧廠遞憲積遞淵(窪鹹鬱壓簾簾窪鏇鹽廠) = 淵蓋醖廠廠齋蓋願糧顧 鬱鹽夢範壓糧製繭衊獵 (選選廠廠淵膚衊網鏇廠 ) 更多 | 积极 | 2020-08-01 | |||
獵糧壓顧廠遞憲積遞淵(窪鹹鬱壓簾簾窪鏇鹽廠) = 鏇構艱艱齋願積觸醖餘 鬱鹽夢範壓糧製繭衊獵 (選選廠廠淵膚衊網鏇廠 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用